Índice Bovespa

US Dollar vs BRL

Cadastre-se para interagir em nossos fóruns de ativos e discutir com investidores ideias semelhantes.

Cadastre-se

OKYO Okyo Pharma Limited

91,00

0,00 (0,00%)

Última atualização: 21:00:00

Atrasado em 15 minutos

Bolsa de Londres: Índice FTSE 100 abre estável nesta sexta-feira, 13 de setembro de 2019

/jornal/2019/09/bolsa-de-londres-indice-ftse-100-abre-estavel-nesta-sexta-feira-13-de-setembro-de-2019/

Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Click aqui para mais gráficos Okyo Pharma.

Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024

Click aqui para mais gráficos Okyo Pharma.

Notícias

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
Segunda, 8 de Abril de 2024 (2 semanas atrás) • UK Regulatory

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
Terça, 2 de Abril de 2024 (3 semanas atrás) • UK Regulatory

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
Sexta, 22 de Março de 2024 (1 mês atrás) • UK Regulatory

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
Quinta, 21 de Março de 2024 (1 mês atrás) • UK Regulatory

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
Quarta, 20 de Março de 2024 (1 mês atrás) • UK Regulatory

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
Sexta, 9 de Fevereiro de 2024 (2 meses atrás) • InvestorsHub NewsWire

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
Sexta, 9 de Fevereiro de 2024 (2 meses atrás) • UK Regulatory

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
Quarta, 31 de Janeiro de 2024 (3 meses atrás) • UK Regulatory

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
Segunda, 8 de Janeiro de 2024 (4 meses atrás) • GlobeNewswire Inc.

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
Sexta, 5 de Janeiro de 2024 (4 meses atrás) • GlobeNewswire Inc.

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
Segunda, 4 de Dezembro de 2023 (5 meses atrás) • GlobeNewswire Inc.

OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
Terça, 31 de Outubro de 2023 (6 meses atrás) • GlobeNewswire Inc.

Mais Notícias de

Índice Bovespa

$Logo da Infracommerce Caxaas ON (IFCM3).$

Infracommerce Caxaas ON

MAGAZINE LUIZA ON

Pet Center Comercio E Pa... ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições